Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC By Ogkologos - May 19, 2026 179 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PLANeT study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... July 29, 2021 Inequalities cause 2,000 extra cancer cases in Wales June 8, 2023 The stories behind Teenage and Young Adult Cancer Awareness Month April 6, 2023 31-Year Breast Cancer Survivor Celebrates 100th Birthday with Drive-By Mardi Gras... December 29, 2020 Load more HOT NEWS Targeted Therapy Based on Molecular Profiling of Malignant Mesothelioma Tumours Is... Genomic and Immunophenotypic Heterogeneity of Acquired Resistance to Immune Checkpoint Inhibitors... Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line...
